Yanxing Chen
YOU?
Author Swipe
View article: EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism
EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism Open
Background Eukaryotic translation regulators have emerged as pivotal modulators of cancer progression and immune evasion. However, their mechanistic contributions in hepatocellular carcinoma (HCC) remain poorly understood. EIF2B4, the δ-su…
View article: Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
Combined HDAC inhibitor, anti-angiogenesis therapy with immunotherapy hastens the immune cells infiltration and functionality in patient sample
View article: Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
The gating strategy of main cell types and T cells through flow cytometry in this article
View article: Supplementary Figure S5 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S5 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
Anti-angiogenesis therapy reverses the vascular abnormalization caused by HDAC inhibitor
View article: Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
The toxicity of Combined HDAC inhibitor with anti-angiogenesis therapy
View article: Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
Vascular abnormalization is associated with the efficacy of HDAC inhibitor combined immunotherapy
View article: Supplementary Figure S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
HDAC inhibitor facilitates the functionality of CD8+ T cells
View article: Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
HDAC inhibitor hinders the infiltration of CD8+ T cells
View article: Supplementary Figure S6 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S6 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
Anti-angiogenesis therapy promotes the infiltration of CD8+ T cells
View article: Data from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Data from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
Immunotherapy has made remarkable strides in the treatment of solid tumors, but its efficacy as a single agent in immunologically cold tumors remains limited. Therefore, it is necessary to explore novel drug combinations to further optimiz…
View article: Supplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
The video of 3D images in tumor tissues treated with CP regimen
View article: Supplementary Video S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Video S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
The video of 3D images in tumor tissues treated with P regimen
View article: Supplementary Figure S8 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S8 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
ombined chidamide with anti-VEGFR-2 antibody facilitates the immunotherapy efficacy in multiple solid tumors
View article: Supplementary Figure S11 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S11 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
The gating strategy of other cell subpopulations through flow cytometry in this article
View article: Supplementary Table 1-4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Table 1-4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
The information about the patients and primers used in this article
View article: Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Open
HDAC inhibitor promotes the expression of VEGFa in macrophage
View article: High density lipoprotein particle size and function associate with new cardiovascular events in patients with chronic kidney disease
High density lipoprotein particle size and function associate with new cardiovascular events in patients with chronic kidney disease Open
Chronic Kidney Disease (CKD) is a risk factor for cardiovascular disease (CVD), and patients with CKD have markedly higher CVD mortality compared to healthy controls. However, the relationship between specific lipoprotein profiles and new …
View article: A combination of transcriptomics and epigenomics identifies genes and regulatory elements involved in embryonic tail development in the mouse
A combination of transcriptomics and epigenomics identifies genes and regulatory elements involved in embryonic tail development in the mouse Open
Our work brings new insights and provides exploitable fundamental datasets for the elucidation of the complex genetic mechanisms responsible for the formation of the vertebrate/mammalian tail.
View article: Supplementary Table 2 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Supplementary Table 2 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
The raw data of 1B.
View article: Supplementary Table 1 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Supplementary Table 1 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
The primer sequences used.
View article: Figure S3 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S3 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S3A: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 overexpressing (TRIM50) versus control empty vector (EV) MKN45 cells (n = 6 mice per group). Scale bar: 1 cm Figure S3B: MKN74 cells were tran…
View article: Data from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Data from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Gastric cancer (GC) is one of the most frequent cancers in the world. Emerging clinical data show that ubiquitination system disruptions are likely involved in carcinoma genesis and progression. However, the precise role of ubiquitin (Ub)-…
View article: Figure S6 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S6 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S6: Immunoblotting analysis of JUP in TRIM50 overexpressing versus control empty vector MKN45 cells.
View article: Figure S7 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S7 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S7: TOPFLASH analysis of JUP in TRIM50 overexpressing versus control empty vector 293T cells.
View article: Figure S5 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S5 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S5: 293T cells were transfected with Myc-TRIM50 plasmid, Flag-JUP plasmid and HA-Ub plasmid, whole-cell lysates were subjected to SDS denaturation and immunoprecipitation with JUP antibody and immunoblot analysis with the indicated …
View article: Figure S2 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S2 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S2: Immunoblotting assay of TRIM50 expression in GC cells.
View article: Figure S7 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S7 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S7: TOPFLASH analysis of JUP in TRIM50 overexpressing versus control empty vector 293T cells.
View article: Figure S3 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP
Figure S3 from TRIM50 inhibits gastric cancer progression by regulating the ubiquitination and nuclear translocation of JUP Open
Figure S3A: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 overexpressing (TRIM50) versus control empty vector (EV) MKN45 cells (n = 6 mice per group). Scale bar: 1 cm Figure S3B: MKN74 cells were tran…